BioNTech reports Q3 2026 results and raises revenue guidance
Third quarter revenues were €1,289.2 million with net profit of €184.5 million; full-year 2026 revenue guidance narrowed to €1.7–1.9 billion.
See the latest news and media coverage for BioNTech. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing immunotherapies and vaccines
biontech.comLast updated
In short: BioNTech posted Q3 profit, raised its 2026 revenue minimum and agreed to acquire an FDA review voucher.
Third quarter revenues were €1,289.2 million with net profit of €184.5 million; full-year 2026 revenue guidance narrowed to €1.7–1.9 billion.
AHEAD-MERIT trial continues to evaluate overall survival as the second endpoint. BNT113 did not meet progression-free survival goals versus pembrolizumab alone.
Gotistobart achieved 18.5 months median overall survival versus 10.0 months for chemotherapy in previously treated squamous non-small cell lung cancer patients.
The company revises full-year revenue guidance to €1.6–1.9 billion due to lower vaccine demand while appointing Guido Oelkers as its next CEO by February 2027.
Biontech is eliminating around 1800 positions and closing sites. How the departure of founders Şahin and Türeci will proceed remains unclear.
The Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report ...
The Mainz-based biotech group BioNTech has returned to profitability in the third quarter and is looking at the full year with somewhat more optimism.
Biontech now expects revenues for the full year of between EUR 1.7 and 1.9 billion, previously the range was between EUR 1.6 and 1.9 billion. Sahin and...
Track BioNTech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to BioNTech and other trending companies.